GR 174152
Latest Information Update: 10 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antiulcers
- Mechanism of Action Cholecystokinin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastro-oesophageal reflux
Most Recent Events
- 06 Dec 2000 Profile reviewed but no significant changes made
- 03 Nov 1998 No-Development-Reported for Gastro-oesophageal reflux in United Kingdom (Unknown route)
- 17 Jul 1996 New profile